

Andres Cervantes

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9003256/andres-cervantes-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

185 papers	16,122 citations	46 h-index	126 g-index
242 ext. papers	20,507 ext. citations	6.8 avg, IF	6.37 L-index

#	Paper	IF	Citations
185	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , 2016 , 27, 1386-422	10.3	1683
184	A phase 3 trial of bevacizumab in ovarian cancer. <i>New England Journal of Medicine</i> , 2011 , 365, 2484-96	59.2	1454
183	ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. <i>Annals of Oncology</i> , 2012 , 23, 2479-2516	10.3	984
182	Capecitabine as adjuvant treatment for stage III colon cancer. <i>New England Journal of Medicine</i> , 2005 , 352, 2696-704	59.2	958
181	Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2016 , 27, v38-v49	10.3	796
180	Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4706-13	2.2	789
179	Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014 , 25 Suppl 3, iii1-9	10.3	702
178	Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2017 , 28, iv22-iv40	10.3	627
177	Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2013 , 24 Suppl 6, vi64-72	10.3	580
176	Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. <i>Lancet Oncology</i> , 2015 , 16, 928-36	21.7	475
175	Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. <i>Annals of Oncology</i> , 2017 , 28, 1713-1729	10.3	454
174	Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018 , 29, iv238-iv255	10.3	355
173	Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2013 , 24 Suppl 6, vi81-8	10.3	345
172	Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. <i>Annals of Oncology</i> , 2010 , 21 Suppl 5, v93-7	10.3	322
171	EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. <i>European Journal of Cancer</i> , 2014 , 50, 1.e1-1.e34	7.5	274
170	Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. <i>Annals of Oncology</i> , 2018 , 29, 44-70	10.3	260
169	Integration of oncology and palliative care: a Lancet Oncology Commission. <i>Lancet Oncology</i> , 2018 , 19, e588-e653	21.7	230

168	Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology, The</i> , 2019 , 20, 849-861	21.7	201
167	Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 862-874	21.7	180
166	First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. <i>Oncologist</i> , 2012 , 17, 15-25	5.7	170
165	Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. <i>European Journal of Surgical Oncology</i> , 2014 , 40, 584-591	3.6	137
164	Unmet needs and challenges in gastric cancer: the way forward. <i>Cancer Treatment Reviews</i> , 2014 , 40, 692-700	14.4	135
163	Current questions for the treatment of advanced gastric cancer. <i>Cancer Treatment Reviews</i> , 2013 , 39, 60-7	14.4	133
162	Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. <i>Annals of Oncology</i> , 2020 , 31, 1320-1335	10.3	121
161	European Society for Medical Oncology (ESMO) position paper on supportive and palliative care. <i>Annals of Oncology</i> , 2018 , 29, 36-43	10.3	120
160	Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2012 , 18, 4764-4774	12.9	119
159	Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. <i>Radiotherapy and Oncology</i> , 2014 , 111, 330-9	5.3	116
158	Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014 , 25 Suppl 3, iii10-20	10.3	112
157	Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2019 , 25, 4888-4897	12.9	110
156	A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors. <i>Cancer Discovery</i> , 2017 , 7, 102-113	24.4	105
155	Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019 , 25, 3220-3228	12.9	99
154	Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. <i>European Journal of Surgical Oncology</i> , 2014 , 40, 1165-76	3.6	98
153	The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios. <i>Cancer Treatment Reviews</i> , 2018 , 70, 1-8	14.4	84
152	Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer. <i>Cancer</i> , 2011 , 117, 3118-25	6.4	76
151	The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target. <i>Cancer Treatment Reviews</i> , 2020 , 86, 102015	14.4	75

150	The treatment of advanced gastric cancer: current strategies and future perspectives. <i>Annals of Oncology</i> , 2008 , 19 Suppl 5, v103-7	10.3	67
149	Short-course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer: The randomized RAPIDO trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4006-4006	2.2	67
148	Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. <i>Annals of Oncology</i> , 2019 , 30, 1804-1812	10.3	64
147	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. <i>Annals of Oncology</i> , 2020 , 31, 334-351	10.3	64
146	Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2019 , 30, 1558-1571	10.3	62
145	Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. <i>Annals of Oncology</i> , 2010 , 21, 1537-1545	10.3	62
144	Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. <i>Annals of Oncology</i> , 2021 , 32, 801-805	10.3	49
143	Context matters-consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials. <i>Annals of Oncology</i> , 2019 , 30, 520-527	10.3	47
142	PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer. <i>Annals of Oncology</i> , 2016 , 27, 1557-65	10.3	47
141	Definition of the Rectum: An International, Expert-based Delphi Consensus. <i>Annals of Surgery</i> , 2019 , 270, 955-959	7.8	45
140	TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	44
139	JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. <i>Annals of Oncology</i> , 2020 , 31, 861-872	10.3	43
138	First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors. <i>Clinical Cancer Research</i> , 2016 , 22, 877-85	12.9	43
137	Efficacy and Determinants of Response to HER Kinase Inhibition in -Mutant Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2020 , 10, 198-213	24.4	41
136	Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 4380-4387	12.9	41
135	Molecular biology of gastric cancer. <i>Clinical and Translational Oncology</i> , 2007 , 9, 208-15	3.6	40
134	Personalized Medicine: Recent Progress in Cancer Therapy. <i>Cancers</i> , 2020 , 12,	6.6	39
133	Treatment of Patients With Early-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline. <i>Journal of Global Oncology</i> , 2019 , 5, 1-19	2.6	37

132	Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy. <i>Annals of Oncology</i> , 2021 , 32, 590-599	10.3	36
131	Quality assurance in the treatment of colorectal cancer: the EURECCA initiative. <i>Annals of Oncology</i> , 2014 , 25, 1485-92	10.3	35
130	Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver. <i>Cancer Cell</i> , 2021 , 39, 708-724.e11	24.3	34
129	Oncological emergencies. <i>Annals of Oncology</i> , 2004 , 15 Suppl 4, iv299-306	10.3	32
128	Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer. <i>Investigational New Drugs</i> , 2018 , 36, 848-859	4.3	31
127	Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system. <i>Clinical and Translational Oncology</i> , 2009 , 11, 787-98	3.6	31
126	Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer. <i>Oncotarget</i> , 2015 , 6, 26935-45	3.3	30
125	NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in -Amplified Gastric Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 1639-1649	12.9	30
124	Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study. <i>European Journal of Cancer</i> , 2019 , 123, 146-154	7.5	29
123	Oncology for medical students: a European School of Oncology contribution to undergraduate cancer education. <i>Cancer Treatment Reviews</i> , 2007 , 33, 419-26	14.4	28
122	Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3568-3568	2.2	27
121	The role of chemotherapy in localized and locally advanced rectal cancer: A systematic revision. <i>Cancer Treatment Reviews</i> , 2018 , 63, 156-171	14.4	26
120	Undergraduate training in oncology: an ESO continuing challenge for medical students. <i>Surgical Oncology</i> , 2012 , 21, 15-21	2.5	26
119	Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. <i>Gynecologic Oncology</i> , 2019 , 152, 53-60	4.9	26
118	Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2015 , 112, 1874-81	8.7	25
117	Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Radiotherapy and Oncology</i> , 2014 , 110, 189-94	5.3	25
116	Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity. <i>Clinical Cancer Research</i> , 2017 , 23, 5406-5415	12.9	24
115	Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma. <i>European Journal of Cancer</i> , 2014 , 50, 496-505	7.5	24

114	Prognostic Nutritional Index as an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer. <i>ESMO Open</i> , 2018 , 3, e000425	6	24
113	Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes. <i>Scientific Reports</i> , 2019 , 9, 7665	4.9	23
112	The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?. <i>Annals of Oncology</i> , 2018 , 29, 1099-1107	10.3	23
111	An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results. <i>Journal of Clinical Oncology</i> , 2004 , 22, 3512-3512	2.2	23
110	Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer. <i>PLoS ONE</i> , 2017 , 12, e0177331	3.7	23
109	Preclinical models for precision oncology. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018 , 1870, 239-246	11.2	22
108	A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. The Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD). <i>Cancer</i> , 1995 , 76, 559-63	6.4	21
107	Adjuvant chemotherapy and relative survival of patients with stage II colon cancer - A EURECCA international comparison between the Netherlands, Denmark, Sweden, England, Ireland, Belgium, and Lithuania. <i>European Journal of Cancer</i> , 2016 , 63, 110-7	7.5	20
106	Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, LBA387-LBA387	2.2	20
105	How we treat metastatic colorectal cancer. <i>ESMO Open</i> , 2020 , 4, e000813	6	20
104	Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis. <i>Gastroenterology Research and Practice</i> , 2018 , 2018, 2373868	2	19
103	The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona. <i>Digestive and Liver Disease</i> , 2016 , 48, 1283-1289	3.3	19
102	Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial. <i>Annals of Oncology</i> , 2015 , 26, 1936-1941	10.3	18
101	Self-expanding metallic stent as a bridge to surgery in the treatment of left colon cancer obstruction: Cost-benefit analysis and oncologic results. <i>Cirugía Española</i> , 2017 , 95, 143-151	0.7	18
100	FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. <i>Gut</i> , 2015 , 64, 921-8	19.2	17
99	Borderline resectable pancreatic cancer. Challenges and controversies. <i>Cancer Treatment Reviews</i> , 2018 , 68, 124-135	14.4	17
98	Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. <i>British Journal of Cancer</i> , 2020 , 123, 1590-1598	8.7	17
97	The McCaVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC). <i>Oncologist</i> , 2020 , 25, e451-e459	5.7	17

96	Early Detection for Colorectal Cancer: ASCO Resource-Stratified Guideline. <i>Journal of Global Oncology</i> , 2019 , 5, 1-22	2.6	16
95	Pathological evaluation of mesocolic resection quality and ex vivo methylene blue injection: what is the impact on lymph node harvest after colon resection for cancer?. <i>Diseases of the Colon and Rectum</i> , 2012 , 55, 197-204	3.1	16
94	Prognostic Impact of pT Stage and Peritoneal Invasion in Locally Advanced Colon Cancer. <i>Diseases of the Colon and Rectum</i> , 2019 , 62, 684-693	3.1	16
93	Low miR200c expression in tumor budding of invasive front predicts worse survival in patients with localized colon cancer and is related to PD-L1 overexpression. <i>Modern Pathology</i> , 2019 , 32, 306-313	9.8	16
92	A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS. <i>Oncologist</i> , 2017 , 22, 1024-e89	5.7	15
91	Assessing molecular subtypes of gastric cancer: microsatellite unstable and Epstein-Barr virus subtypes. Methods for detection and clinical and pathological implications. <i>ESMO Open</i> , 2019 , 4, e000478	7	15
90	Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers. <i>Future Oncology</i> , 2018 , 14, 1629-1645	3.6	14
89	Precision medicine in the adjuvant treatment of gastric cancer. <i>Lancet Oncology, The</i> , 2018 , 19, 583-584	21.7	14
88	5-Fluorouracil, folinic acid, epidoxorubicin and cisplatin (FLEP) combination chemotherapy in advanced measurable gastric cancer. A phase II trial of the Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD). <i>Annals of Oncology</i> , 1993 , 4, 753-7	10.3	14
87	Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences. <i>Clinical Cancer Research</i> , 2021 ,	12.9	14
86	Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. <i>Carcinogenesis</i> , 2016 , 37, 852-7	4.6	13
85	Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016 , 160, 69-77	4.4	13
84	Intracellular signalling via the AKT axis and downstream effectors is active and prognostically significant in cancer of unknown primary (CUP): a study of 100 CUP cases. <i>Annals of Oncology</i> , 2012 , 23, 2725-2730	10.3	13
83	Training in communication of oncology clinicians: a position paper based on the third consensus meeting among European experts in 2018. <i>Annals of Oncology</i> , 2018 , 29, 2033-2036	10.3	13
82	Epigenetic changes in localized gastric cancer: the role of RUNX3 in tumor progression and the immune microenvironment. <i>Oncotarget</i> , 2016 , 7, 63424-63436	3.3	12
81	Treatment sequence of synchronously (liver) metastasized colon cancer. <i>Digestive and Liver Disease</i> , 2016 , 48, 1119-23	3.3	12
80	Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma. <i>Annals of Oncology</i> , 2019 , 30, 1254-1264	10.3	11
79	Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors. <i>Annals of Oncology</i> , 2020 , 31, 626-633	10.3	11

78	Exploring better strategies for EGFR antibodies in colon cancer. <i>Lancet Oncology, The</i> , 2014 , 15, 549-50	21.7	11
77	Prognostic implications of the standardized study of resection margins in pancreatic cancers. <i>Cirugía Española</i> , 2014 , 92, 532-8	0.7	11
76	Progress in the multidisciplinary treatment of gastrointestinal cancer and the impact on clinical practice: perioperative management of rectal cancer. <i>Annals of Oncology</i> , 2008 , 19 Suppl 7, vii266-72	10.3	11
75	Final results of the McCAVE trial: A double-blind, randomized phase 2 study of vanucizumab (VAN) plus FOLFOX vs. bevacizumab (BEV) plus FOLFOX in patients (pts) with previously untreated metastatic colorectal carcinoma (mCRC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3539-3539	2.2	11
74	Personalised Treatment in Gastric Cancer: Myth or Reality?. <i>Current Oncology Reports</i> , 2016 , 18, 41	6.3	11
73	GAIN-(C): Efficacy and safety analysis of imgatuzumab (GA201), a novel dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), in combination with FOLFIRI compared to cetuximab plus FOLFIRI in second-line KRAS exon 2 wild type (c2WT) or with FOLFIRI alone in mutated (c2MT) metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 669-679	2.2	10
72	Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer. <i>Cancers</i> , 2020 , 12,	6.6	9
71	A multimodality approach to localized rectal cancer. <i>Annals of Oncology</i> , 2006 , 17 Suppl 10, x129-34	10.3	9
70	Role of epigenetic factors in the selection of the alternative splicing isoforms of human in colorectal cancer cell lines. <i>Oncotarget</i> , 2018 , 9, 20578-20589	3.3	9
69	Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology. <i>Oncotarget</i> , 2016 , 7, 22543-55	3.3	9
68	In silico RNA-seq and experimental analyses reveal the differential expression and splicing of EPDR1 and ZNF518B genes in relation to KRAS mutations in colorectal cancer cells. <i>Oncology Reports</i> , 2016 , 36, 3627-3634	3.5	9
67	MassARRAY determination of somatic oncogenic mutations in solid tumors: Moving forward to personalized medicine. <i>Cancer Treatment Reviews</i> , 2016 , 49, 57-64	14.4	9
66	EGF-Induced Acetylation of Heterogeneous Nuclear Ribonucleoproteins Is Dependent on KRAS Mutational Status in Colorectal Cancer Cells. <i>PLoS ONE</i> , 2015 , 10, e0130543	3.7	8
65	The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper. <i>Radiotherapy and Oncology</i> , 2020 , 142, 6-16	5.3	8
64	Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). <i>ESMO Open</i> , 2016 , 1, e000107	6	8
63	Circulating tumor DNA analysis for assessment of recurrence risk, benefit of adjuvant therapy, and early relapse detection after treatment in colorectal cancer patients.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 11-11	2.2	8
62	Clinical management of metastatic colorectal cancer in the era of precision medicine.. <i>Ca-A Cancer Journal for Clinicians</i> , 2022 ,	220.7	8
61	EPDR1 up-regulation in human colorectal cancer is related to staging and favours cell proliferation and invasiveness. <i>Scientific Reports</i> , 2020 , 10, 3723	4.9	7

60	Liquid biopsy: another tool towards tailored therapy in colorectal cancer. <i>Annals of Oncology</i> , 2018 , 29, 7-8	10.3	7
59	Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	7
58	Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review. <i>Cancers</i> , 2021 , 13,	6.6	7
57	Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. <i>Annals of Oncology</i> , 2021 , 32, 1496-1510	10.3	7
56	Combination of KIR2DS4 and FcRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer. <i>Scientific Reports</i> , 2019 , 9, 2589	4.9	6
55	Clinical pharmacokinetics and pharmacodynamics of ramucirumab in the treatment of colorectal cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 449-56	5.5	6
54	Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer. <i>ESMO Open</i> , 2020 , 5, e000847	6	6
53	Trends and outcome of neoadjuvant treatment for rectal cancer: A retrospective analysis and critical assessment of a 10-year prospective national registry on behalf of the Spanish Rectal Cancer Project. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 276-284	3.6	6
52	Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2019 , 112, 12-19	7.5	5
51	ZNF518B gene up-regulation promotes dissemination of tumour cells and is governed by epigenetic mechanisms in colorectal cancer. <i>Scientific Reports</i> , 2019 , 9, 9339	4.9	5
50	Aurora kinases in ovarian cancer. <i>ESMO Open</i> , 2020 , 5, e000718	6	5
49	Panex: A pooled analysis of EXPERT and EXPERT-C, two trials of neoadjuvant chemotherapy (NACT) and chemoradiotherapy (CRT) in high-risk locally advanced rectal cancer (LARC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3575-3575	2.2	5
48	A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer. <i>ESMO Open</i> , 2019 , 4, e000532	6	5
47	Changing the education paradigm in oncology: ESO masterclass, 17 years of continuous success. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 146, 102798	7	5
46	A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment. <i>Investigational New Drugs</i> , 2020 , 38, 1774-1783	4.3	4
45	The Medical Oncology resident mentor: situation and workload. <i>Clinical and Translational Oncology</i> , 2019 , 21, 304-313	3.6	4
44	A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019 , 178, 121-133	4.4	4
43	Primary paraesophageal Ewing@ sarcoma: an uncommon case report and literature review. <i>OncoTargets and Therapy</i> , 2015 , 8, 1053-9	4.4	4

42	ESO-ESMO Masterclass in Clinical Oncology: Analysis and Evaluation of the Learning Self-Assessment Test. <i>Journal of Cancer Education</i> , 2021 , 36, 556-560	1.8	4
41	Radiomics and radiogenomics in head and neck squamous cell carcinoma: Potential contribution to patient management and challenges. <i>Cancer Treatment Reviews</i> , 2021 , 99, 102263	14.4	4
40	Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study. <i>British Journal of Cancer</i> , 2021 , 125, 1261-1269	8.7	4
39	Improving tumour budding evaluation in colon cancer by extending the assessment area in colectomy specimens. <i>Histopathology</i> , 2019 , 75, 517-525	7.3	3
38	Abstract P6-12-02: Phase Ib dose-escalation study of an Akt inhibitor ipatasertib (Ipat) in combination with docetaxel (Doc) or paclitaxel (Pac) in patients (pts) with metastatic breast cancer (MBC) 2015 ,		3
37	Circulating tumor DNA to detect minimal residual disease, response to adjuvant therapy, and identify patients at high risk of recurrence in patients with stage I-III CRC.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4009-4009	2.2	3
36	New localization and function of calpain-2 in nucleoli of colorectal cancer cells in ribosomal biogenesis: effect of KRAS status. <i>Oncotarget</i> , 2018 , 9, 9100-9113	3.3	3
35	Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer. <i>ESMO Open</i> , 2019 , 4, e000519	6	3
34	Clinical Case Presentation and Discussion During ESO-ESMO Masterclass: a 10-Year Interactive Educational Experience. <i>Journal of Cancer Education</i> , 2021 , 36, 1124-1128	1.8	3
33	Molecular profile in Paraguayan colorectal cancer patients, towards to a precision medicine strategy. <i>Cancer Medicine</i> , 2019 , 8, 3120-3130	4.8	2
32	RAS mutations in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab (C) in MRI-defined, high-risk rectal cancer (RC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 489-489	2.2	2
31	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS3634-TPS3634	2.2	2
30	Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre. <i>ESMO Open</i> , 2020 , 5, e000929	6	2
29	Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data. <i>Clinical Colorectal Cancer</i> , 2021 , 20, 227-235	3.8	2
28	First-In-Human Phase I Study of a Next-Generation, Oral, TGF β Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2021 ,	12.9	2
27	Extending neoadjuvant chemotherapy in rectal cancer. <i>Lancet Oncology, The</i> , 2015 , 16, 880-1	21.7	1
26	Emerging strategies in the treatment of advanced esophageal, gastroesophageal junction, and gastric cancer: the introduction of targeted therapies. <i>Targeted Oncology</i> , 2006 , 1, 23-33	5	1
25	Prognostic effect of a single nucleotide polymorphism (SNP) in MIR608 in patients with high-risk locally advanced rectal cancer (LARC): Results of the EXPERT-C trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 581-581	2.2	1

24	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS789-TPS789	2.2	1
23	mRNA expression profiles obtained from microdissected pancreatic cancer cells can predict patient survival. <i>Oncotarget</i> , 2017 , 8, 104796-104805	3.3	1
22	Impact of perioperative transfusions and sepsis on long-term oncologic outcomes after curative colon cancer resection. A retrospective analysis of a prospective database. <i>Gastroenterology & Hepatology</i> , 2020 , 43, 63-72	0.9	1
21	Computational Evaluation and In Vitro Validation of New Epidermal Growth Factor Receptor Inhibitors. <i>Current Topics in Medicinal Chemistry</i> , 2020 , 20, 1628-1639	3	1
20	Ten-year assessment of a cancer fast-track programme to connect primary care with oncology: reducing time from initial symptoms to diagnosis and treatment initiation. <i>ESMO Open</i> , 2021 , 6, 100148	6	1
19	First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 1	7.4	1
18	First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers.. <i>Cancer Chemotherapy and Pharmacology</i> , 2022 , 89, 499	3.5	1
17	Mechanisms of skin toxicity of paclitaxel: An in vitro preclinical assessment.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e15511-e15511	2.2	0
16	Colorectal cancer survival: prevalence of psychosocial distress and unmet supportive care needs. <i>Supportive Care in Cancer</i> , 2021 , 1	3.9	0
15	In the literature: February 2017. <i>ESMO Open</i> , 2017 , 2, e000171	6	
14	In the literature: April 2017. <i>ESMO Open</i> , 2017 , 2, e000193	6	
13	Impact of perioperative transfusions and sepsis on long-term oncologic outcomes after curative colon cancer resection. A retrospective analysis of a prospective database. <i>Gastroenterology & Hepatology (English Edition)</i> , 2020 , 43, 63-72	0.1	
12	Reply to the letter to the editor Q How much evidence is nQ in evidence-based guidelines? Q by Johnson et al. <i>Annals of Oncology</i> , 2016 , 27, 550-1	10.3	
11	Growth factor receptor-related therapy for gastric cancer. <i>European Journal of Cancer</i> , 2011 , 47 Suppl 3, S324-5	7.5	
10	In the literature: October 2018. <i>ESMO Open</i> , 2018 , 3, e000447	6	
9	A preclinical model for skin sensitization prediction of antineoplastic drugs.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e15643-e15643	2.2	
8	Phase 1 study of biweekly (Q2W) anti-EGFR monoclonal antibody (mAb) mixture Sym004 in patients (pts) with metastatic colorectal cancer (mCRC) resistant to previous anti-EGFR treatment.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3551-3551	2.2	
7	Relationship of RAS and TP53 predictive value for cetuximab (C) benefit: Results of the EXPERT-C trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 447-447	2.2	

6	Educational needs in gastrointestinal cancer: a consensus position paper from the ESMO Gastrointestinal Cancer Faculty. <i>ESMO Open</i> , 2019 , 4, e000533	6
5	In the literature: December 2018. <i>ESMO Open</i> , 2018 , 3, e000468	6
4	In the literature: August 2018. <i>ESMO Open</i> , 2018 , 3, e000427	6
3	Reply to the letter to the editor: adjuvant nivolumab for the management of the pathological residual disease in esophageal or junctional tumors: a word of caution by P.K. Garg, R. Kumar and P. Dixit. <i>Annals of Oncology</i> , 2021 , 32, 1190-1191	10.3
2	Peritoneal invasion and metachronous peritoneal metastases after colon cancer surgery: The role of homogeneous, reliable assessment and confounders. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 2697	3.6
1	Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer. <i>Seminars in Oncology</i> , 1997 , 24, S15-40-S15-43	5.5